[CLINICAL EVALUATION OF THE PROTEO-ANABOLIC ACTIVITY OF L-METHYL-DELTA ANDROSTENOLONE IN PATIENTS WITH MALIGNANT NEOPLASMS DURING ACTINOTHERAPY].
D045930:Anabolic Agents; D001797:Blood Protein Electrophoresis; D001943:Breast Neoplasms; D002283:Carcinoma, Bronchogenic; D003036:Cobalt Isotopes; D003687:Dehydroepiandrosterone; D005260:Female; D006801:Humans; D008175:Lung Neoplasms; D009369:Neoplasms / Q000532:radiotherapy* / Q000628:therapy*; D010051:Ovarian Neoplasms; D011883:Radium; D013256:Steroids; D014467:Ultraviolet Therapy; D014594:Uterine Neoplasms
D045930:Anabolic Agents; D003036:Cobalt Isotopes; D013256:Steroids; D003687:Dehydroepiandrosterone; D011883:Radium
ANABOLIC STEROIDS; BLOOD PROTEIN ELECTROPHORESIS; BREAST NEOPLASMS; CARCINOMA, BRONCHOGENIC; COBALT ISOTOPES; LUNG NEOPLASMS; NEOPLASM RADIOTHERAPY; NEOPLASM THERAPY; OVARIAN NEOPLASMS; RADIUM; UTERINE NEOPLASMS
VALUTAZIONE CLINICA DELL'ATTIVIT'A PROTEO-ANABOLICA DELL'1-METIL-DELTA ANDROSTENOLONE IN PAZIENTI PORTATORI DI NEOPLASIE MALIGNE NEL CORSO DI ATTINOTERAPIA.